Cyclic Nucleotide Phosphodiesterases and Human Arterial Smooth Muscle Cell Proliferation
- 1 January 1999
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (08), 424-434
- https://doi.org/10.1055/s-0037-1615862
Abstract
Smooth muscle cells (SMCs) in the arterial wall are normally found in a contractile, nonproliferative state. These SMCs are continuously exposed to agents that elevate cyclic AMP (cAMP) and cyclic GMP (cGMP), such as prostacyclin and nitric oxide (NO) released from the endothelium. Both cAMP and cGMP potently inhibit SMC proliferation by antagonizing major signaling pathways induced by growth factors, such as platelet-derived growth factor. Different forms of injury to the endothelium result in proliferation of the SMCs and can develop into atherosclerosis, restenosis, or arterial thickening associated with neonatal pulmonary hypertension. In human adult aorta, cAMP and cGMP levels are tightly regulated by synthesis and degradation. The latter is mediated by at least two different cAMP phosphodiesterases (PDEs), PDE3 and PDE4, and three different PDEs that degrade mainly cGMP, PDE1A, PDE1B, and PDE5. Strikingly, expression of a new PDE that degrades both cAMP and cGMP, PDE1C, is markedly induced in proliferating SMCs from the same aorta in culture, whereas its expression is nondetectable in contractile aorta. We propose that, for a human arterial SMC to be able to efficiently proliferate, and perhaps even to undergo a phenotypic change from a quiescent to a proliferative phenotype, it has to efficiently degrade inhibitory cAMP and cGMP. In human SMCs, PDE1C is induced to degrade these cyclic nucleotides. Understanding the role of PDE1C in SMC proliferation may provide the basic information necessary for development of highly specific PDE1C inhibitors that target proliferating SMCs in cardiovascular disease.Keywords
This publication has 60 references indexed in Scilit:
- Crosstalk Between Protein Kinase A and Growth Factor Receptor Signaling Pathways in Arterial Smooth MuscleCellular Signalling, 1999
- Does Nitric Oxide Regulate Smooth Muscle Cell Proliferation?Journal of Vascular Research, 1998
- Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cellsJournal Of Hypertension, 1997
- Nitric Oxide Reversibly Inhibits the Migration of Cultured Vascular Smooth Muscle CellsCirculation Research, 1996
- Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction.The Journal of cell biology, 1995
- Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors.JCI Insight, 1995
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Smooth muscle cells and the pathogenesis of the lesions of atherosclerosisHeart, 1993
- Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cellsBiochemical Journal, 1992
- Cell cycle-dependent inhibition of human vascular smooth muscle cell proliferation by prostaglandin E1Experimental Cell Research, 1985